SCHWIND AMARIS: already providing excellent results

Article

Schwind eye-tech-solution's latest unveiling, the SCHWIND AMARIS excimer laser, provides excellent visual acuity (VA) results, high predictability and low variance in results.

Schwind eye-tech-solution's latest unveiling, the SCHWIND AMARIS excimer laser, provides excellent visual acuity (VA) results, high predictability and low variance in results, according to Maria-Clara Arbelaez, MD from Oman, speaking at the Schwind lunchtime symposium.

Dr Arbelaez's claims follow the results of a multicentre study, which was conducted by the Oman doctor along with Ioannis Aslanides, MD (Greece), Francesco Carones, MD (Italy), Tobias Neuhann, MD (Germany), as well as Alena Feuermannova, MD and Pavel Rozsival, MD (Czech Republic). The purpose of the study was to evaluate the outcomes of AMARIS-LASIK aberration free treatments for myopia and myopic astigmatism.

A total of 454 myopic eyes, either pure or with astigmatism, underwent "Aberration Free" treatment with the SCHWIND AMARIS. Preoperative spherical equivalent (SE) ranged from -0.50 D to -8.5 D (mean -3.54 D±1.67 D) and sphere and cylinder was treated up to -9 D and -7 D, respectively.

The mean postoperative SE at one-month follow-up was -0.16 with a low standard deviation of 0.26 D. In 74% of eyes, the planned refractive result was achieved within ±0.25 D after one month, 93% were within ±0.50 D and 100% were within ±1.00 D. High postoperative stability was observed after just one week.

By one-month follow-up, 92% of eyes had attained an uncorrected visual acuity (UCVA) of 20/20 or better, 99% of eyes achieved a UCVA of 20/25 or better and 43% of eyes achieved a VA of 20/16 or better. No eyes had a VA of less than 20/32.

"These results were obtained without applying additional nomograms," confirmed Dr Arbelaez. "In my opinion, the extraordinary performance of the SCHWIND AMARIS decisively contributed to the excellent clinical results that we have seen so far. Although further follow-up is required to evaluate overall stability, I truly believe that aberration free treatments with the Schwind AMARIS are safe and predictable," she concluded.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.